Vaxart Defends Board in Proxy Fight, Announces $29M BARDA Funding for COVID-19 Trial Data Unblinding
VXRT has more than doubled off its 52-week low of $0.261.
Summary
Vaxart filed additional proxy materials, updating its investor presentation to defend its board against an activist shareholder group and announce a BARDA contract modification that provides an additional $29 million and enables the imminent unblinding of key Phase 2b COVID-19 trial data.
Key Events · Corporate Governance and Compliance · VXRT
-
BARDA Contract Modification & Funding
Vaxart announced a required modification to its BARDA contract, releasing an additional $29 million for the completion of its Phase 2b COVID-19 trial and exploratory analyses. The overall funding for the trial is now approximately $345 million.
-
Imminent Clinical Data Readout
The BARDA modification enables Vaxart to unblind, analyze, and report 12-month safety and immunogenicity data from the 400-participant Sentinel Cohort of its COVID-19 trial in the coming weeks.
-
Proxy Contest Defense
The company is actively soliciting shareholder votes for its six current director nominees, presenting arguments against the dissident shareholder group and criticizing their nominees' qualifications and motivations.
-
Financial Runway Extended
Vaxart reaffirmed its financial runway into Q2 2027, citing prudent capital allocation, strategic partnerships, and focused resource management, building on its Q1 2026 financial turnaround.
Analysis · VXRT · Life Sciences
This filing is a critical communication in Vaxart's ongoing proxy contest, where the company is actively defending its current board and strategy against an activist shareholder group. The updated investor presentation provides new arguments against the dissident nominees, highlighting their perceived lack of relevant experience. More importantly, it announces a significant BARDA contract modification, which includes an additional $29 million in funding for the Phase 2b COVID-19 trial and enables the imminent unblinding and reporting of 12-month safety and immunogenicity data from the 400-participant Sentinel Cohort. This funding and data readout are crucial operational and financial milestones for a clinical-stage biotech company, directly impacting its lead program and extending its financial runway into Q2 2027. The outcome of the proxy vote will determine the future leadership and strategic direction of the company, while the BARDA update provides a concrete positive development for its core business.
At the time of this filing, VXRT was trading at $0.54 on OTC in the Life Sciences sector, with a market capitalization of approximately $130.6M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.